Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Products tagged as GENERIC have had a generic equivalent approved for at least one strength of the product.
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4713394 Treatment of nonacne inflammatory and infectious dermatoses and hair loss Claim Types: Method of use | Jan 17, 2006 | U-492: Method for the treatment of skin, suffering from a condition selected from a group consisting of non-acne inflammatory dermatoses comprising applying to affected area a therapeutically effective amt azelaic acid |
| Pat. No. 6534070 Composition with azelaic acid Claim Types: Formulation; Method of use | Nov 18, 2018 |
MIVACRON; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER (INJECTABLE) MIVACURIUM CHLORIDE
NDA Applicant: ABBOTT NDA No.: 020098 Prod. No.: 001 RX (EQ 2MG BASE/ML) NDA No.: 020098 Prod. No.: 002 DISC (EQ 0.5MG BASE/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4761418 [Extended 173 days (0.5 years)] Novel compounds Claim Types: Compound; Composition; Method of use | Jan 22, 2006 |
IPRIVASK (INJECTABLE) DESIRUDIN RECOMBINANT
NDA Applicant: CANYON NDA No.: 021271 Prod. No.: 001 RX (15MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4801576 Method of inhibiting blood clotting with desulfatohirudins Claim Types: Method of use | Jan 31, 2006 | |
| Pat. No. 5733874 Stable dry powders Claim Types: Formulation | Mar 31, 2015 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | APR 04,2008 |
NICOTROL (INHALANT) NICOTINE
Drug Classes: CNS, MISCELLANEOUS
NDA Applicant: PHARMACIA AND UPJOHN NDA No.: 020714 Prod. No.: 001 RX (4MG/CARTRIDGE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4800903 Nicotine dispenser with polymeric reservoir of nicotine Claim Types: Device; Formulation; Process | Jan 31, 2006 | |
| Pat. No. 5167242 Nicotine-impermeable container and method of fabricating the same Claim Types: Device | Jun 8, 2010 | |
| Pat. No. 5400808 Nicotine-impermeable container and method of fabricating the same Claim Types: Device; Process | Jun 8, 2010 | |
| Pat. No. 5501236 Nicotine-impermeable container and method of fabricating the same Claim Types: Device | Jun 8, 2010 | |
| Pat. No. 6098632 Nicotine-impermeable container and method of fabricating the same Claim Types: Device | Jun 8, 2010 |
MAXAQUIN (TABLET) LOMEFLOXACIN HYDROCHLORIDE
Drug Classes: ANTIBACTERIALS, MISCELLANEOUS
NDA Applicant: PHARMACIA NDA No.: 020013 Prod. No.: 001 RX (EQ 400MG BASE)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4528287 [Extended 522 days* (1.4 years)] 6-Fluoro-1, 4-dihydro-4-oxo-7-substituted piperazinylquinoline-3-carboxylic acids and the method for preparing the same Claim Types: Compound; Composition; Method of use | Feb 21, 2006 | U-36: Methods of treating bacterial illnesses |
FLOMAX (CAPSULE) TAMSULOSIN HYDROCHLORIDE
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: BOEHRINGER INGELHEIM NDA No.: 020579 Prod. No.: 001 RX (0.4MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4772475 Controlled-release multiple units pharmaceutical formulation Claim Types: Product-by-process | Feb 27, 2006 | |
| Pat. No. 4868216 Sulfamoyl-substituted phenethylamine derivatives and process of producing them Claim Types: Method of use | Sep 19, 2006 | U-181: Producing alpha adrenergic antagonistic action in a host |
| Pat. No. 4703063 [Extended 5 years] Sulfamoyl substituted phenethylamine derivatives and process of producing them Claim Types: Compound; Composition | Oct 27, 2009 |
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE (TABLET, EXTENDED RELEASE) PSEUDOEPHEDRINE HYDROCHLORIDE
NDA Applicant: ALZA NDA No.: 020021 Prod. No.: 002 OTC (240MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4801461 Pseudoephedrine dosage form Claim Types: Device | Mar 14, 2006 |
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE (TABLET, EXTENDED RELEASE) BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
NDA Applicant: ALZA NDA No.: 019672 Prod. No.: 001 OTC (16MG;240MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4662880 Pseudoephedrine, brompheniramine therapy Claim Types: Device | Mar 14, 2006 | |
| Pat. No. 4801461 Pseudoephedrine dosage form Claim Types: Device | Mar 14, 2006 | |
| Pat. No. 4810502 Pseudoephedrine brompheniramine therapy Claim Types: Device | Mar 14, 2006 |
PERIOCHIP (TABLET) CHLORHEXIDINE GLUCONATE
Drug Classes: ANTISEPTICS/DISINFECTANTS
NDA Applicant: DEXCEL PHARMA NDA No.: 020774 Prod. No.: 001 RX (2.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 5002769 Compositions for the sustained-release of chlorhexidine Claim Types: Formulation; Method of administration | Mar 16, 2006 |
NOVANTRONE (INJECTABLE) MITOXANTRONE HYDROCHLORIDE
Drug Classes: ANTINEOPLASTICS
NDA Applicant: SERONO INC NDA No.: 019297 Prod. No.: 001 RX (EQ 20MG BASE/10ML(2MG/ML))
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4820738 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof Claim Types: Method of use | Apr 11, 2006 | U-98: A method of inducing regression of leukemia cell growth in a mammal |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code ODE: Orphan Drug | OCT 13,2007 | Treatment of progressive-relapsing multiple sclerosis. |
| Exclusivity Code ODE: Orphan Drug | OCT 13,2007 | Treatment of secondary-progressive multiple sclerosis. |
NOVANTRONE (INJECTABLE) MITOXANTRONE HYDROCHLORIDE [GENERIC AP]
Drug Classes: ANTINEOPLASTICS
NDA Applicant: SERONO INC NDA No.: 019297 Prod. No.: 002 RX (EQ 25MG BASE/12.5ML (2MG/ML)); 003 RX (EQ 30MG BASE/15ML (2MG/ML))
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4820738 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof Claim Types: Method of use | Apr 11, 2006 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code ODE: Orphan Drug | OCT 13,2007 | Treatment of progressive-relapsing multiple sclerosis. |
| Exclusivity Code ODE: Orphan Drug | OCT 13,2007 | Treatment of secondary-progressive multiple sclerosis. |
PRAVACHOL (TABLET) PRAVASTATIN SODIUM [GENERIC AB]
Drug Classes: HYPERLIPIDEMIA; CARDIOVASCULAR-RENAL
NDA Applicant: BRISTOL MYERS SQUIBB NDA No.: 019898 Prod. No.: 002 RX (10MG); 003 RX (20MG); 004 RX (40MG); 008 RX (80MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4346227 [Extended 1598 days (4.4 years)] ML-236B Derivatives and their preparation Claim Types: Compound | Apr 20, 2006 *PED | |
| Pat. No. 5030447 Pharmaceutical compositions having good stability Claim Types: Formulation | Jan 9, 2009 *PED | |
| Pat. No. 5180589 Pravastatin pharmaceuatical compositions having good stability Claim Types: Formulation; Process | Jan 9, 2009 *PED | |
| Pat. No. 5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor Claim Types: Method of use | Oct 22, 2014 *PED | U-335: Use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: I - New Indication | Apr 29,2006 PED | I-370: Treatment of heterozygous familial hypercholesterolemia in children, ages 8-13 years, with recommended dose of 20mg once daily and in adolescents, ages 14-18 with a recommended dose of 40mg once daily |
PRAVIGARD PAC (COPACKAGED) (TABLET, TABLET) ASPIRIN; PRAVASTATIN SODIUM
Drug Classes: CARDIOVASCULAR-RENAL; HYPERLIPIDEMIA
NDA Applicant: BRISTOL MYERS SQUIBB NDA No.: 021387 Prod. No.: 001 RX (81MG,N/A;N/A,20MG); 002 RX (81MG,N/A;N/A,40MG); 003 RX (81MG,N/A;N/A,80MG); 004 RX (325MG,N/A;N/A,20MG); 005 RX (325MG,N/A;N/A,40MG); 006 RX (325MG,N/A;N/A,80MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4346227 [Extended 1598 days (4.4 years)] ML-236B Derivatives and their preparation Claim Types: Compound | Apr 20, 2006 *PED | |
| Pat. No. 5030447 Pharmaceutical compositions having good stability Claim Types: Formulation | Jan 9, 2009 *PED | |
| Pat. No. 5180589 Pravastatin pharmaceuatical compositions having good stability Claim Types: Formulation; Process | Jan 9, 2009 *PED | |
| Pat. No. 5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor Claim Types: Method of use | Oct 22, 2014 *PED | U-335: Use of pravastatin sodium for secondary prevention of coronary events in men and women who have had a myocardial infarction and have normal cholesterol levels |
HEPSERA (TABLET) ADEFOVIR DIPIVOXIL
NDA Applicant: GILEAD NDA No.: 021449 Prod. No.: 001 RX (10MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4724233 Therapeutical application of phosphonylmethoxyalkyl adenines Claim Types: Method of use | Apr 21, 2006 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 4808716 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof Claim Types: Compound | Apr 25, 2006 | |
| Pat. No. 5663159 DS* DP* Prodrugs of phosphonates Claim Types: Compound; Method of use | Sep 2, 2014 | U-470: Therapy in chronic hepatitis B virus infection |
| Pat. No. 6451340 DS* DP* Nucleotide analog compositions Claim Types: New polymorph, salt or hydrate; Method of use; Process; Product-by-process; Formulation | Jul 23, 2018 | U-470: Therapy in chronic hepatitis B virus infection |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | SEP 20,2007 |
LUPRON DEPOT (INJECTABLE) LEUPROLIDE ACETATE
Drug Classes: ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION; ANTINEOPLASTICS
NDA Applicant: TAP PHARM NDA No.: 020011 Prod. No.: 001 RX (3.75MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Sep 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 5631021 Method for producing microcapsule Claim Types: Product-by-process | May 20, 2014 |
LUPRON DEPOT; LUPRON DEPOT-4 (INJECTABLE) LEUPROLIDE ACETATE
Drug Classes: ANTINEOPLASTICS
NDA Applicant: TAP PHARM NDA No.: 020517 Prod. No.: 001 RX (22.5MG/VIAL); 002 RX (30MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5814342 Prolonged release microcapsules Claim Types: Formulation; Process | Feb 1, 2011 | |
| Pat. No. 5480656 Prolonged release microcapsules Claim Types: Formulation | Jan 2, 2013 | |
| Pat. No. 5643607 Prolonged release microcapsules Claim Types: Formulation; Process | Jan 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Nov 19, 2013 | |
| Pat. No. 5631020 Method for producing microcapsule Claim Types: Product-by-process; Process | May 20, 2014 | |
| Pat. No. 6036976 Sustained release microspheres and preparation thereof Claim Types: Product-by-process | Dec 13, 2016 |
LUPRON DEPOT (INJECTABLE) LEUPROLIDE ACETATE
Drug Classes: ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION; ANTINEOPLASTICS; ESTROGENS/PROGESTINS
NDA Applicant: TAP PHARM NDA No.: 019732 Prod. No.: 001 RX (7.5MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Sep 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 5631020 Method for producing microcapsule Claim Types: Product-by-process; Process | May 20, 2014 | |
| Pat. No. 6036976 Sustained release microspheres and preparation thereof Claim Types: Product-by-process | Dec 13, 2016 |
LUPRON DEPOT-3 (INJECTABLE) LEUPROLIDE ACETATE
Drug Classes: ANTERIOR PITUITARY/HYPOTHALMIC FUNCTION; ANTINEOPLASTICS
NDA Applicant: TAP PHARM NDA No.: 020708 Prod. No.: 001 RX (11.25MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5814342 Prolonged release microcapsules Claim Types: Formulation; Process | Feb 1, 2011 | |
| Pat. No. 5480656 Prolonged release microcapsules Claim Types: Formulation | Jan 2, 2013 | |
| Pat. No. 5643607 Prolonged release microcapsules Claim Types: Formulation; Process | Jan 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Nov 19, 2013 | |
| Pat. No. 5631020 Method for producing microcapsule Claim Types: Product-by-process; Process | May 20, 2014 | |
| Pat. No. 6036976 Sustained release microspheres and preparation thereof Claim Types: Product-by-process | Dec 13, 2016 |
LUPRON DEPOT-PED (INJECTABLE) LEUPROLIDE ACETATE
NDA Applicant: TAP PHARM NDA No.: 020263 Prod. No.: 002 RX (7.5MG/VIAL); 005 RX (11.25MG/VIAL); 006 RX (15MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Sep 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 5631020 Method for producing microcapsule Claim Types: Product-by-process; Process | May 20, 2014 | |
| Pat. No. 6036976 Sustained release microspheres and preparation thereof Claim Types: Product-by-process | Dec 13, 2016 |
LUPRON DEPOT-PED (INJECTABLE) LEUPROLIDE ACETATE
NDA Applicant: TAP PHARM NDA No.: 020263 Prod. No.: 003 DISC (3.75MG/VIAL,7.5MG/VIAL); 004 DISC (7.5MG/VIAL,7.5MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4728721 Polymer, production and use thereof Claim Types: Excipient; Process | May 1, 2006 | |
| Pat. No. 4849228 Polymer, production and use thereof Claim Types: Formulation | Jul 18, 2006 | |
| Pat. No. 5575987 Method of producing sustained-release microcapsules Claim Types: Formulation | Sep 2, 2013 | |
| Pat. No. 5716640 Method of producing sustained-release microcapsules Claim Types: Formulation; Process | Sep 2, 2013 | |
| Pat. No. 6036976 Sustained release microspheres and preparation thereof Claim Types: Product-by-process | Dec 13, 2013 | |
| Pat. No. 5631020 Method for producing microcapsule Claim Types: Product-by-process; Process | May 20, 2014 |
ACTIVELLA (TABLET) ESTRADIOL; NORETHINDRONE ACETATE
Drug Classes: ESTROGENS/PROGESTINS
NDA Applicant: NOVO NORDISK INC NDA No.: 020907 Prod. No.: 001 RX (1MG;0.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 |
EXOSURF NEONATAL (FOR SUSPENSION) CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL
NDA Applicant: GLAXOSMITHKLINE NDA No.: 020044 Prod. No.: 001 DISC (12MG/VIAL;108MG/VIAL;8MG/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4826821 Lung surfactant compositions Claim Types: Formulation | May 2, 2006 | |
| Pat. No. 5110806 Lung surfactant compositions Claim Types: Formulation | May 2, 2006 |
PREMPHASE 14/14 (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Drug Classes: ESTROGENS/PROGESTINS; CONTRACEPTIVES
NDA Applicant: WYETH PHARMS INC NDA No.: 020527 Prod. No.: 002 RX (0.625MG,0.625MG;N/A,5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | |
| Pat. No. 5547948 Controlled release of steroids from sugar coatings Claim Types: Formulation | Jan 17, 2015 |
PREMPRO (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Drug Classes: ESTROGENS/PROGESTINS; CONTRACEPTIVES
NDA Applicant: WYETH PHARMS INC NDA No.: 020527 Prod. No.: 001 RX (0.625MG;2.5MG); 003 RX (0.625MG;5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | U-284: Menopausal and postmenopausal disorders (including vasomotor symptoms associated with menopause, and vulvar and vaginal atrophy) and osteoporosis |
| Pat. No. 5547948 Controlled release of steroids from sugar coatings Claim Types: Formulation | Jan 17, 2015 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | MAR 12,2006 | D-79: New lower starting dose for treatment of moderate to severe vasomotor symptoms and/or moderate to severe symptoms of vulvar and vaginal atrophy associated w/ the menopause |
PREMPRO (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Drug Classes: ESTROGENS/PROGESTINS; CONTRACEPTIVES
NDA Applicant: WYETH PHARMS INC NDA No.: 020527 Prod. No.: 004 RX (0.45MG;1.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | |
| Pat. No. 5547948 Controlled release of steroids from sugar coatings Claim Types: Formulation | Jan 17, 2015 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | MAR 12,2006 | D-79: New lower starting dose for treatment of moderate to severe vasomotor symptoms and/or moderate to severe symptoms of vulvar and vaginal atrophy associated w/ the menopause |
| Exclusivity Code: D - New Dosing Schedule | JUN 04,2006 | D-81: New lower starting dose for the prevention of postmenopausal osteoporosis |
| Exclusivity Code: NP - New product | MAR 12,2006 |
PREMPRO (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Drug Classes: ESTROGENS/PROGESTINS; CONTRACEPTIVES
NDA Applicant: WYETH PHARMS INC NDA No.: 020527 Prod. No.: 005 RX (0.3MG;1.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | |
| Pat. No. 5547948 Controlled release of steroids from sugar coatings Claim Types: Formulation | Jan 17, 2015 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: D - New Dosing Schedule | JUN 04,2006 | D-81: New lower starting dose for the prevention of postmenopausal osteoporosis |
| Exclusivity Code: NS - New strength | JUN 04,2006 |
PREMPRO (PREMARIN;CYCRIN) (TABLET) ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
NDA Applicant: WYETH PHARMS INC NDA No.: 020303 Prod. No.: 001 DISC (0.625MG,0.625MG;2.5MG,2.5MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. RE36247 Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens Claim Types: Method of use; Formulation | May 2, 2006 | U-284: Menopausal and postmenopausal disorders (including vasomotor symptoms associated with menopause, and vulvar and vaginal atrophy) and osteoporosis |
| Pat. No. 5210081 Alkali metal 8,9-dehydroestrone sulfate esters Claim Types: Composition | Feb 26, 2012 |
FERIDEX I.V. (INJECTABLE) FERUMOXIDES
Drug Classes: DIAGNOSTICS, RADIOPAQUE & NONRADIOACTIVE
NDA Applicant: ADV MAGNETICS NDA No.: 020416 Prod. No.: 001 RX (EQ 11.2MG IRON/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4827945 Biologically degradable superparamagnetic materials for use in clinical applications Claim Types: Diagnostic or surgical method; Method of use | May 9, 2006 | U-144: Biologically degradable superparamagnetic materials for use in clinical applications |
| Pat. No. 4951675 Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging Claim Types: Diagnostic or surgical method | Aug 28, 2007 | U-143: Biodegradable superparamagnetic metal oxides as contrast agents for mr imaging |
| Pat. No. 5055288 Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides Claim Types: Composition | Oct 8, 2008 | |
| Pat. No. 5102652 Low molecular weight carbohydrates as additives to stabilize metal oxide compositions Claim Types: Formulation; Diagnostic or surgical method; Method of use; Process | Feb 6, 2009 | |
| Pat. No. 5219554 Hydrated biodegradable superparamagnetic metal oxides Claim Types: Composition | Jun 15, 2010 | |
| Pat. No. 5248492 Low molecular weight carbohydrates as additives to stabilize metal oxide compositions Claim Types: Formulation; Diagnostic or surgical method; Method of use; Method of improving a formulation | Sep 28, 2010 |
GASTROMARK (SUSPENSION) FERUMOXSIL
Drug Classes: DIAGNOSTICS, MISCELLANEOUS
NDA Applicant: ADV MAGNETICS NDA No.: 020410 Prod. No.: 001 RX (EQ 0.175MG IRON/ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4827945 Biologically degradable superparamagnetic materials for use in clinical applications Claim Types: Diagnostic or surgical method; Method of use | May 9, 2006 | U-170: Method of obtaining an mr image using the composition/drug product as a contrast agent |
| Pat. No. 5069216 Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract Claim Types: Diagnostic or surgical method | May 9, 2006 | U-171: Methods of using the compound/drug product as an oral contrast agent in magnetic resonance imaging of the gastrointestinal tract |
| Pat. No. 5055288 Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides Claim Types: Composition | Oct 8, 2008 | |
| Pat. No. 5219554 Hydrated biodegradable superparamagnetic metal oxides Claim Types: Composition | Jun 15, 2010 |
FLOLAN (INJECTABLE) EPOPROSTENOL SODIUM
Drug Classes: ANTIHYPERTENSIVES
NDA Applicant: GLAXOSMITHKLINE NDA No.: 020444 Prod. No.: 001 RX (EQ 0.5MG BASE/VIAL); 002 RX (EQ 1.5MG BASE/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4883812 [Extended 1347 days (3.7 years)] Treatment of hypertension using prostacyclin Claim Types: Method of use | May 12, 2006 | U-185: Method of treating hypertension |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code ODE: Orphan Drug | APR 14,2007 | Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease. |
PYTEST; PYTEST KIT (CAPSULE) UREA, C-14
Drug Classes: DIAGNOSTICS - RADIOPHARMACEUTICALS
NDA Applicant: BALLARD MEDCL NDA No.: 020617 Prod. No.: 001 RX (1uCi); 002 RX (1uCi)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4830010 [Extended 1260 days (3.5 years)] Methods for the diagnosis of gastrointestinal disorders Claim Types: Diagnostic or surgical method Comments: Extension applies to MERETEK and BREATHTEK, but not PYTEST for which this patent is also listed. For PYTEST, the Orange Book expiration date is incorrect. The actual expiration date is May 16, 2006. | May 15, 2006 | U-195: Method for the diagnosis of gastrointestinal disorders by urea isotoac or nitrogen labeled carbon |
NEUTREXIN (INJECTABLE) TRIMETREXATE GLUCURONATE
Drug Classes: ANTINEOPLASTICS
NDA Applicant: MEDIMMUNE ONCOLOGY NDA No.: 020326 Prod. No.: 001 RX (EQ 25MG BASE/VIAL)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4694007 Use of trimetrexate as antiparasitic agent Claim Types: Method of use | May 20, 2006 | U-91: Alternative therapy to trimethoprim-sulfamethoxazole for treatment of moderate-to-severe pneumocystis carinii pneumonia in immunocompromised and aids patients |
| Pat. No. 6017922 Thermally stable trimetrexates and processes for producing the same Claim Types: New polymorph, salt or hydrate; Composition | May 18, 2018 |
NASAREL (SPRAY, METERED) FLUNISOLIDE
Drug Classes: CORTICOSTEROIDS-INHALATION/NASAL
NDA Applicant: IVAX RES NDA No.: 020409 Prod. No.: 001 RX (0.029MG/SPRAY)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4782047 Aqueous steroid formulations for nasal administration Claim Types: Formulation; Method of use | May 22, 2006 | |
| Pat. No. 4983595 Aqueous steroid formulations for nasal administration Claim Types: Formulation | May 22, 2006 | |
| Pat. No. 4933168 Stable, crystalline flunisolide Claim Types: New polymorph, salt or hydrate; Formulation; Method of use | Jun 12, 2007 |
ADVIL, CHILDREN'S (SUSPENSION) IBUPROFEN [Has competitive generic]
NDA Applicant: WYETH CONS NDA No.: 019833 Prod. No.: 002 RX (100MG/5ML)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4788220 Pediatric ibuprofen compositions Claim Types: Formulation | May 29, 2006 *PED |
METROGEL (GEL) METRONIDAZOLE [GENERIC AB]
Drug Classes: ANTIBACTERIALS, MISCELLANEOUS; DERMATOLOGICS
NDA Applicant: GALDERMA LABS LP NDA No.: 019737 Prod. No.: 001 RX (0.75%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4837378 Topical metronidazole formulations and therapeutic uses thereof Claim Types: Formulation; Method of use | Jun 6, 2006 |
METROGEL-VAGINAL (GEL) METRONIDAZOLE
Drug Classes: ANTIBACTERIALS, MISCELLANEOUS; ANTIPROTOZOALS
NDA Applicant: 3M NDA No.: 020208 Prod. No.: 001 RX (0.75%)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4837378 Topical metronidazole formulations and therapeutic uses thereof Claim Types: Formulation; Method of use | Jun 6, 2006 | |
| Pat. No. 5840744 Intravaginal treatment of vaginal infections with buffered metronidazole compositions Claim Types: Formulation; Method of use; Drug in a container | Jan 15, 2008 | U-370: Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| Pat. No. 5536743 Intravaginal treatment of vaginal infections with buffered metronidazole compositions Claim Types: Formulation; Method of use | Jul 16, 2013 | U-137: Method of treating bacterial vaginosis |
SPECTRACEF (TABLET) CEFDITOREN PIVOXIL
Drug Classes: CEPHALOSPORINS
NDA Applicant: PURDUE PHARMA LP NDA No.: 021222 Prod. No.: 001 RX (200MG)
| Patents | Expiration | Patented Use |
|---|---|---|
| Pat. No. 4918068 Cephem compounds Claim Types: Compound; Composition | Jun 13, 2006 | |
| Pat. No. 4839350 DS* DP* [Extended 1036 days (2.8 years)] Cephalosporin compounds and the production thereof Claim Types: Compound; Composition | Apr 14, 2009 | |
| Pat. No. 5958915 Antibacterial composition for oral administration Claim Types: Formulation; Method of improving a formulation | Oct 14, 2016 | |
| Exclusivity | Expiration | Exclusivity Description |
| Exclusivity Code: NCE - New chemical entity | AUG 29,2006 |
MACROBID (CAPSULE) NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE [GENERIC AB]
Drug Classes: